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Accuracy of in-utero MRI to detect fetal brain abnormalities 
and prognosticate developmental outcome: postnatal 
follow-up of the MERIDIAN cohort
Anthony R Hart, Nicholas D Embleton, Michael Bradburn, Daniel J A Connolly, Laura Mandefield, Cara Mooney, Paul D Griffiths
Summary
Background In utero MRI (iuMRI) detects fetal brain abnormalities more accurately than ultrasonography and provides 
additional clinical information in around half of pregnancies. We aimed to study whether postnatal neuroimaging 
after age 6 months changes the diagnostic accuracy of iuMRI and its ability to predict developmental outcome.
Methods Families enrolled in the MERIDIAN study whose child survived to age 3 years were invited to have a case 
note review and assessment of developmental outcome with the Bayley Scales of Infant and Toddler Development, 
the Ages and Stages Questionnaire, or both. A paediatric neuroradiologist, masked to the iuMRI results, reviewed the 
postnatal neuroimaging if the clinical report difered from iuMRI indings. Diagnostic accuracy was recalculated. 
A paediatric neurologist and neonatologist categorised participants’ development as normal, at risk, or abnormal, and 
the ability of iuMRI and ultrasonography to predict developmental outcome were assessed.
Findings 210 participants had case note review, of whom 81 (39%) had additional investigations after age 6 months. The 
diagnostic accuracy of iuMRI remained higher than ultrasonography (proportion of correct cases was 529 [92%] 
of 574 vs 387 [67%] of 574; absolute diference 25%, 95% CI 21 to 29; p<0·0001). Developmental outcome data were 
analysed in 156 participants, and 111 (71%) were categorised as normal or at risk. Of these 111 participants, prognosis 
was normal or favourable for 56 (51%) using ultrasonography and for 76 (69%) using iuMRI (diference in speciicity 
18%, 95% CI 7 to 29; p=0·0008). No statistically signiicant diference was seen in infants with abnormal outcome 
(diference in sensitivity 4%, 95% CI –10 to 19; p=0·73).
Interpretation iuMRI remains the optimal tool to identify fetal brain abnormalities. It is less accurate when used to 
predict developmental outcome, although better than ultrasonography for identifying children with normal outcome. 
Further work is needed to determine how the prognostic abilities of iuMRI can be improved.
Funding National Institute for Health Research Health Technology Assessment programme.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
The MERIDIAN study1 showed that in utero MRI 
(iuMRI) detects fetal brain abnormalities more 
accurately than ultrasonography alone.2 iuMRI also 
improves diagnostic conidence and provides additional 
useful clinical information in 49% of women, which 
changes prognosis in 24%.1 Subsequent work in smaller 
cohorts of women3,4 and a meta-analysis5 have also 
conirmed the superiority of iuMRI over ultrasono-
graphy, although the numbers of additional abnor-
malities detected by iuMRI were smaller than the 
MERIDIAN study. 
The diferences in detection are likely to relect local 
antenatal care practices, including whether ultra-
sonography was done abdominally or transvaginally, 
and the MERIDIAN study relects the role of iuMRI in 
UK clinical practice, where transvaginal ultra-
sonography is not routinely done in all pregnant 
women.
The outcome reference diagnoses (ORD) used in the 
MERIDIAN study were either post-mortem results or 
neuro imaging done in the irst 6 months of life, which 
was predominately cranial ultrasound. It is possible the 
neuro imaging ORD were incorrect or incomplete, and 
there is little published data to show how accurately 
ultra sonography and iuMRI provide prognostic infor-
mation on developmental outcomes. 
Understanding the accuracy of these methods is 
important because women and their families want to 
know the signiicance of any abnormalities found 
antenatally.6–8 The MERIDIAN 3-year follow-up study 
was designed to address these knowledge gaps across 
three projects, speciically: project one was designed 
to recalculate the diagnostic accuracy of ultrasonography 
and iuMRI using diagnoses collected after 6 months 
of age; project two, to compare the ability of ultrasono-
graphy and iuMRI to predict developmental outcome 
around age 3 years; and project three, to study the devel-
op mental signiicance of isolated mild ventriculomegaly 
(IMVM), because of the large numbers of cases and 
perceived di culties in antenatal prog nostication in this 
cohort.
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Methods
Study design and participants
The MERIDIAN 3-year follow-up study was an extension 
of the original MERIDIAN study, in which all families 
were asked to provide written consent to be contacted 
about future studies. Ethical approval was obtained and it 
was overseen by a trial steering committee. Section 251 
conidentiality advisory group approval was obtained for 
use of the Health & Social Care Information Centre Patient 
Tracking system to ensure potentially eligible children 
were alive before approach. If the child had died, the date 
and cause of death were obtained but no contact was made 
with the family. Children were excluded if they were no 
longer in the care of the biological mother or if the mother 
was unable to understand English and no family member 
could translate. A letter of invitation, consent form, and a 
developmental screening questionnaire (the Ages and 
Stages Questionnaire 3rd edition;9 ASQ3) were sent to the 
families of eligible children. Families could consent for 
either project one or all projects. The full protocol is 
available online.
Procedures
Families who consented to their child’s participation in 
project one agreed to a review of their child’s case notes 
and neuroimaging reports. If the latest report did not 
match the original ORD, or if an ORD study had not 
been done within the irst 6 months of life, a paediatric 
neuroradiologist (DJAC) reviewed the neuroimaging 
report. As in the original study,1 cases in which the 
iuMRI was done more than 2 weeks after ultrasonography 
were excluded. Families who consented to project one 
Research in context
Evidence before this study
In utero MRI (iuMRI) is increasingly used in antenatal care when 
ultrasonography detects a fetal brain abnormality. The 
MERIDIAN study showed that iuMRI has better diagnostic 
accuracy than ultrasonography, obtaining the correct diagnosis 
in 93% of cases compared with postnatal imaging before age 
6 months or post-mortem findings. Obstetricians reported that 
the results of iuMRI provided information that improved their 
diagnostic confidence and directly informed choices about the 
care of half of the pregnant women whose fetus had a 
suspected brain abnormality on ultrasonography. There is 
limited evidence on how iuMRI relates to postnatal imaging 
after age 6 months, and its ability to predict developmental 
outcome in infancy. We searched PubMed from inception to 
Oct 11, 2019, with no language restrictions. Search terms for in 
utero imaging or fetal brain abnormalities included “Fetus 
[MESH] AND magnetic resonance imaging [MESH]”, 
“Pregnancy [MESH] AND magnetic resonance imaging 
[MESH]”, “Prenatal ultrasonography [MESH]”, “In-utero MRI 
[title/abstract]”, “In-utero Magnetic resonance imaging [title/
abstract]”, “Fet* magnetic resonance imaging [title/abstract]”. 
“Fet* imaging [title/abstract]”, “Prenatal magnetic resonance 
imaging [title/abstract]”, “Prenatal MRI [title/abstract]”, 
“Prenatal imaging [title/abstract]”, “Fet* brain 
abnormalit*[title/abstract]”, “Fet* brain disorder [title/
abstract]”. Search terms for child development included “Child 
development [MESH]”, “Developmental disabilities [MESH]”, 
“Development* outcome [title/abstract]”, “Developmental 
impairment [title/abstract]”, “Developmental delay [title/
abstract]”, “Child development [title/abstract]”. These two 
strategies were then combined using the AND function. 
Numerous articles showed the superiority of iuMRI to detect 
brain abnormalities compared with prenatal ultrasonography, 
including the MERIDIAN study. No article has directly compared 
the prognostic abilities of prenatal ultrasonography and iuMRI 
with reference to child development. The articles studying 
developmental outcome look at a small number of fetal 
conditions, such as ventriculomegaly or agenesis of the corpus 
callosum, but all articles of developmental outcome either 
included small numbers of participants or reviewed outcome 
early in childhood or without formal developmental testing.
Added value of this study
This study provides follow-up data on children diagnosed with a 
brain abnormality in utero, highlighting its diagnostic accuracy: 
it is rare for iuMRI to miss brain abnormalities that are visible on 
postnatal imaging after age 6 months. Its ability to 
prognosticate developmental outcome is less clear. Our results 
suggest that iuMRI is better at identifying children with normal 
outcome compared with ultrasonography, possibly by moving 
fetuses with an intermediate prognosis on ultrasonography to a 
more accurate favourable or normal prognosis. However, the 
developmental scores in our cohort were similar between both 
ultrasonography and iuMRI and also between prognosis groups, 
highlighting that both imaging modalities have their limitations.
Implications of all the available evidence
iuMRI detects brain abnormalities with high diagnostic 
accuracy, confirming its role in antenatal care, and there 
appears to be little additional value in routine postnatal 
imaging, given the chance of changing the diagnosis is small. 
Although obstetricians report that the information obtained 
from iuMRI often changes the information they give pregnant 
women, both ultrasonography and iuMRI are poor predictors of 
outcome. Clinicians providing antenatal counselling should be 
aware of this fact when offering prognostication, and avoid 
overconfidence when discussing the developmental significance 
of brain abnormalities. This is true for significant structural 
abnormalities and of more subtle changes, such as isolated mild 
ventriculomegaly, that are usually associated with good 
outcome. It remains to be seen to whether the accuracy of 
prognostication improves when paediatricians with experience 
following up children with neurological and developmental 
abnormalities are involved in multidisciplinary team discussions 
about the significance of ultrasonography and iuMRI results.
For the full protocol see 
https://www.sheffield.ac.uk/
meridian/2-3yrstudy
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could also return the ASQ3, even if they did not consent 
to project two. Families who consented to project two 
were invited to a developmental assessment using the 
Bayley Scales of Infant and Toddler Development 3rd 
edition10 (BSID3), a self-report questionnaire of the 
Gross Motor Function Classiication Score11 (GMFCS), 
and the Strengths and Di culties questionnaire12 (SDQ). 
If families were not willing to attend, or if the child was 
older than age 42 months, they were asked to complete 
the question naires only. The results of project two were 
combined with ASQ3 results.
Data on developmental outcome from the medical 
records, questionnaires, and the BSID3 assessments 
were reviewed independently by a paediatric neurologist 
(ARH) and a neonatologist (NDE), both of whom were 
masked to the ultrasonography iuMRI results, and ORD. 
Participants were categorised as normal, at risk, or 
abnormal (table 1). The results of the BSID3 took 
precedent over the ASQ3. Disagreement on develop-
mental outcome was resolved by consensus discussion. 
For borderline cases, the results of the SDQ were taken 
into account, with a score of more than 16 taken to be 
abnormal (SDQ scale 0–40).
In the MERIDIAN study,1 obstetricians independently 
provided a prediction of the fetus’ developmental outcome 
on the basis of the ultrasonography and iuMRI results as 
normal (chance of abnormal development no greater than 
the general population), favourable (≤10% chance of 
abnormal development), intermediate (10–50% chance of 
abnormal development), poor (>50% chance of abnormal 
development), or unknown. 
In project three, the develop mental outcomes of children 
with antenatal diagnosis of IMVM were reviewed. 
We included all participants in this analysis, irrespective of 
the time between imaging, because we were not comparing 
ultrasonography to iuMRI.
Statistical analysis
The original MERIDIAN sample size calculation was 
applicable for project one because the 6-month diagnosis 
was retained unless additional diagnostic information 
was obtained. For projects two and three, the sample size 
was constrained by the number of MERIDIAN partici-
pants whose families consented to further study. The 
sample size for project two was informed by the number 
of fetuses whose prognosis changed as a result of the 
iuMRI (n=312), of whom a further 63 were reclassiied as 
the poorest prognosis, and assumed approximately 
400 surviving infants. Scaling these prevalences down, 
400 infants would provide 90% power to detect a 20% 
increase in sensitivity and a 10% increase in speciicity at 
a two-sided signiicance level of 5%. For project three, 
with approximately 140 cases and assuming poor 
outcome was less than 10%, allowing estimation of the 
prevalence to within a standard error of 2·5%.13
For project one, the updated imaging was used to 
recalculate diagnostic accuracy. Developmental outcome 
in relation to ultrasonography and iuMRI was sum-
marised by sensitivity, speciicity, positive predictive 
value (PPV), and negative predictive value (NPV; table 1). 
Speciicities and sensitivities of ultrasonography and 
iuMRI were compared using the McNemar paired 
sample χ² test, with the diference and 95% CIs calculated 
using the Wilson score method. We studied the ability of 
ASQ3 to diagnose abnormal development on BSID3, to 
assess whether it was appro priate to include participants 
with only ASQ3 results in our analysis. Sensitivities and 
speciicities were calculated. All statistical analyses were 
done using R, version 3.5.2, and Stata 15.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
Article. The inal author had full access to all the data in 
the study and had inal responsibility for the decision to 
submit for publication.
Results
The low of the 829 participants from the original 
MERIDIAN study into each of the three projects is 
shown in igure 1. The characteristics of the women 
involved in the study are summarised in the 
appendix (p 1). The families of 238 children consented to 
Definition
Statistical definitions used for diagnostic accuracy in surviving infants
Specificity 100 × (number of cases with normal or at risk development AND favourable or normal 
prognosis/number of cases with normal or at risk development).
Sensitivity 100 × (number of cases with abnormal development AND poor prognosis/number 
of cases with abnormal development).
Negative predictive 
value
100 × (number of cases with normal or at risk development AND favourable or normal 
prognosis/number of cases with favourable or normal prognosis).
Positive predictive 
value
100 × (number of cases with abnormal development AND poor prognosis/number 
of cases with poor prognosis).
Definitions used when assessing the ability to predict in-utero death, stillbirth or death during 
infanthood
Sensitivity 
(mortality)
100 × (number of deceased participants with poor prognosis/number of deceased 
participants). No other attempts were made to incorporate deaths into measures of 
positive predictive value, negative predictive value, or termination of pregnancy into 
measures of prognosis.
Definitions used for developmental outcome
Normal All BSID3 scores above 85 and no diagnosis of cerebral palsy OR; if BSID3 not done, 
where all ASQ3 scores were above the cut-off point and no diagnosis of cerebral palsy 
OR; if BSID3 and ASQ3 data not available but information from clinical notes indicated 
normal developmental outcome.
At risk Any BSID3 scores between 70 and 85 OR; if BSID not done where two or more ASQ3 
scores were near the cut off-level but above the cut-off level in all other domains OR; 
the child had cerebral palsy but motor abilities on the BSID3, or the ASQ3 were normal 
and GMFCS 1 or both.
Abnormal One or more BSID3 composite score below 70 OR; if BSID not done, where ASQ3 scores 
were below the cut-off level in two or more developmental domains OR; ASQ3 scores 
were below the cut-off level in one domain and near the cut-off level in two or more 
domains; OR; the child had cerebral palsy with GMFCS of 2 or greater.
BSID3=Bayley Scales of Infant and Toddler Development 3rd Edition. ASQ3=Ages and Stages Questionnaire 3rd 
Edition. GMFCS=Gross Motor Function Classification System.
Table 1: Definitions used in the MERIDIAN 3-year study
See Online for appendix
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project one. Case notes were available for review in 210 of 
238 children, of whom 81 (39%) had further investigations 
between age zero and 42 months (median 4 months), 
most commonly by postnatal MRI (n=38) or clinical 
assessment (n=34). Data on the reasons for the further 
investigations were not collected. 
Figure 1: Study profile
ASQ=Ages and Stages 
Questionnaire. ORD=outcome 
reference diagnoses. 
BSID3=Bayley Scales of Infant 
and Toddler Development 
3rd Edition. ASQ3=ASQ 
3rd Edition. GMFCS=Gross 
Motor Function Classification 
Score. SDQ=Strengths and 
Difficulties questionnaire.*Did 
not complete assessment: 
participants who consented, 
but then either did not attend 
or cancelled; assessment 
incomplete: participants who 
attended, but the whole 
assessment could not be 
completed or a developmental 
score obtained. †52 completed 
ASQ as part of project 1 and 
were included in project 2. 
‡11 had developmental 
outcome available in medical 
notes and were included in 
project 2.
829 MERIDIAN cohort with completed imaging
615 screened
576 eligible
554 sent invitation letter
317 agreed to initial consent
238 consented to MERIDIAN follow on
 106 project 1 only
 132 project 1 and 2
214 could not be approached
 177 died in original MERIDIAN study
 25 died since MERIDIAN study
 8 child outcome unknown
 2 withdrew from original MERIDIAN study
 2 not screened, reason unknown
65 stillbirth, in-utero demise or infant death, had 
 ultrasonography and iuMRI within 2 weeks of 
 each other and complete prognostic data
 44 deaths within MERIDIAN 
 21 deaths since MERIDIAN
     2 unlikely to be related to fetal brain 
 abnormality
  10 brain sufficiently abnormal that might 
 have contributed to death
 3 syndromic type diagnosis likely to be 
 associated with short lifespan where 
 brain abnormality was a marker of a  
 more widespread problem
 6 reason for death could not be coded
39 ineligible at screening
 12 did not want to be contacted
 3 unable to confirm if child alive
 12 child no longer in care of mother
 12 inappropriate to contact
196 did not respond or no contact
 41 declined entry
 6 no time
 2 not interested
 18 did not want to be contacted
 15 other
79 did not consent
 2 not enough time
 53 consent form not received
 10 no reason given
 13 not contacted
 1 other
22 invitation letter could not be sent
238 consented to project 1
28 notes not available for review
81 neuroimaging after age of 6 months
10 information changing ORD
71 did not have information changing ORD
210 notes available for review
129 no updated neuroimaging
132 consented to project 2
5 did not complete assessment 
 or assessment incomplete*
190 data reviewed by developmental outcome panel‡
221 developmental outcome or mortality 
 data available for analysis of project 2
 156 developmental assessment
 65 mortality data
34 excluded from analysis
 26 did not have ultrasonography and 
 iuMRI within 2 weeks of each other
  8 no prognosis offered by obstetrician 
 after iuMRI
179 completed at least one form of developmental 
 assessment†
 88 BSID3 
 175 ASQ3
 31 GMFCS
 102 SDQ
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The ORD was unchanged in 71 (88%) of 81 cases. In 
five (6%) of 81 cases, the more recent ORD disagreed 
with the original ORD, and in a further five cases (6%) 
the post-6 month neuroimaging studies provided the 
only ORD (table 2). One participant had iuMRI more 
than 2 weeks after ultrasonography and was excluded 
from the recalculation. The recalculated diagnostic 
accuracies for ultrasonography and iuMRI, based 
on the refreshed ORD from 574 cases in total, 
were similar to those in the MERIDIAN study and 
the statistically significant differ ence in diagnostic 
accuracy was maintained (absolute difference 25%, 
95% CI 21–29; p<0·0001; table 3).13 Developmental 
outcome data were available for 190 participants, of 
whom 164 had iuMRI within 2 weeks of ultra-
sonography (appendix p 3). Eight participants did not 
have a prognosis recorded after ultrasonography or 
iuMRI because the clinician did not record this at the 
time of counselling, leaving 156 participants who had 
been given an antenatal prognosis by obstetricians for 
analysis. 
The BSID3 scores were similar between imaging 
modality and prognosis groups in all developmental 
domains (igure 2). 111 (71%) of 156 infants had 
developmental outcomes considered normal or at risk—of 
these infants, 56 (50%) of 111 had a normal or favourable 
prognosis on ultrasonography, compared with 76 (68%) 
following iuMRI (diference in speciicity 18%, 95% CI 
7–29; p=0·0008). 
No statistically signiicant diferences were seen in the 
proportions of fetuses who died or who had abnormal 
development in childhood after being given a poor 
prognosis after ultrasonography or iuMRI (table 4).
The results for all children, irrespective of the time 
between ultrasonography and iuMRI, were similar 
(appendix p 4). The proportion of children in each 
prognostic category who had either abnormal or 
combined abnormal and at risk outcomes are shown 
in table 5. Normal or favourable prognostic groups from 
ultrasonography and iuMRI data were associated with 
abnormal outcomes in approxi mately 20% of cases 
(ultrasonography 18 of 85 cases; iuMR 21 of 109 cases), 
and either abnormal or atypical outcome in around 35% 
of cases (ultrasonography 30 of 85 cases; iuMR 38 of 
109 cases). A normal prognosis was associated with 
normal outcome in around 65% of cases (ultrasonography 
55 of 85; iuMR 71 of 109).
19 (22%) of 86 participants diagnosed with IMVM had 
abnormal development and 12 (14%) of 86 participants 
were considered at risk.13 None of the children received 
a poor prognosis category on antenatal imaging with either 
modality. Abnormal outcome was less likely in cases of 
resolved IMVM than persisting IMVM: IMVM resolved in 
62 (72%) of 86 participants, nine (15%) of whom had 
abnormal outcome, and was persistent in 24 (28%) of 
86 participants, ten (42%) of whom had abnormal outcome. 
15 (17%) of 86 children had post natally diagnosed structural 
or genetic abnormalities or signiicant life events, and 
these were proportionately more common in children with 
abnormal (seven [37%] of 19) and at-risk (four [33%] of 12) 
development compared with normal outcome (four [7%] 
of 54; table 1). 84 participants had both ASQ3 and BSID3 
Ultrasonography diagnosis iuMRI diagnosis Outcome reference diagnosis 
at age 6 months
Outcome reference diagnosis 
at age 3 years*
1 Ventriculomegaly, hypoplastic 
cerebellar hemispheres
Ventriculomegaly Ventriculomegaly Rhombencephalosyapsis
2 Ventriculomegaly Ventriculomegaly Ventriculomegaly Ventriculomegaly, subependymal 
heterotopia
3 Ventriculomegaly, hypogenesis of 
corpus callosum
Ventriculomegaly Ventriculomegaly (due to 
hydrocephalus)
Tectal plate tumour, hydrocephalus due 
to aqueduct stenosis, subependymal 
heterotopia
4 Hypoplastic cerebellar hemispheres Hypoplastic cerebellar 
hemispheres
Hypoplastic cerebellar 
hemispheres
Hypoplastic cerebellar hemispheres, 
subependymal heterotopia
5 Agenesis of corpus callosum Hypogenesis of corpus callosum Hypogenesis of corpus 
callosum
Hypogenesis of corpus callosum, cyst 
of the quadrigeminal cistern, 
polymicrogyria
6† Ventriculomegaly, hypogenesis of 
corpus callosum
Ventriculomegaly, hypogenesis 
of corpus callosum
Not done Ventriculomegaly
7 Agenesis of corpus callosum Agenesis of corpus callosum
Polymicrogyria
Not done Agenesis of corpus callosum, 
polymicrogyria
8 Absent cerebellum Ventriculomegaly, Chiari II 
malformation
Not done Ventriculomegaly, Chiari II malformation
9 Ventriculomegaly, agenesis of corpus 
callosum
Ventriculomegaly Not done Ventriculomegaly
10 Hypoplastic cerebellar vermis Posterior fossa cyst Not done Dandy-Walker spectrum abnormality
iuMRI=in-utero MRI. *In all cases the outcome reference diagnosis at 3 years was determined using MRI. †This case was not included in final analysis because iuMRI occurred 
more than 2 weeks after the ultrasonography.
Table 2: The ten cases with updated outcome reference diagnosis
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(appendix p 5) irrespective of the time between iuMRI and 
ultra sonography. The sensitivity of the ASQ3 was 90%, 
speciicity 83%, PPV 68%, and NPV 97%.
Discussion
Clinical outcomes beyond the immediate postnatal 
period have not been reported in studies comparing 
ultrasonography and iuMRI, which is important because 
features like the immature myelination state of the brain 
can hamper the diagnostic capacity of MRI before age 
6 months. Our results show that postnatal imaging after 
age 6 months rarely changes ORD and the improved 
diagnostic accuracy of iuMRI is maintained.
The developmental signiicance of antenatally diagnosed 
brain abnormalities is important for parents, who use the 
information to decide whether they have the ability, and 
emotional and inancial resources to care for their 
child.6–8,14 Data on many fetal brain abnormalities that can 
be used during antenatal counselling are scarce,15,16 and 
whether iuMRI improves prognostication is unclear. 
The interpretation of our indings is not straightforward. 
Among the 111 infants with normal or at risk develop-
ment, more participants had good prognosis with iuMRI 
compared with ultrasonography, suggesting iuMRI is 
better at excluding abnormal developmental outcome 
than ultrasonography, either through better visualisation 
of the abnormalities or identiication of false positives on 
ultrasonography. The percentage of infants with normal 
or at risk developmental outcome after a good iuMRI 
prognosis was similar to a good prognosis on ultra-
sonography. The discrepancy between speciicity and 
NPVs is likely to be secondary for two reasons. First, 
iuMRI was associated with fewer unknown or 
intermediate prognoses than ultrasonography, often 
moving the fetus into normal, favourable, or poor 
prognosis groups. 
Consequently, although the NPVs were similar, iuMRI 
had improved prognostic accuracy compared with 
ultrasonography. This observation might be because 
iuMRI delineates or excludes other abnormalities better 
than ultrasonography, but there might also be a psycho-
logical factor, whereby iuMRI gives the clinician more 
conidence to move from an indeterminate to either 
Meridian Meridian 3-year follow-up
Ultrasonography 
correct
iuMRI correct Ultrasonography 
correct
iuMRI correct Percentage 
difference (95% CI)
p value*
18–23 weeks (n=372) 256/369 (70%) 341/369 (92%) 257/372 (69%) 339/372 (91%) 22% (17–27) <0·0001
≥24 weeks (n=202) 129/201 (64%) 188/201 (94%) 130/202 (64%) 190/202 (94%) 30% (23–37) <0·0001
Combined (n=574) 387/570 (68%) 529/570 (93%) 387/574 (67%) 529/574 (92%) 25% (21–29) <0·0001
Data are n/N (%), unless otherwise indicated. The 574 fetuses include the 570 fetuses included in the original MERIDIAN primary analysis (had iuMRI within 2 weeks 
of ultrasonography and had outcome reference diagnosis). There were four further cases that now have an outcome reference diagnosis from the 3-year data, increasing 
the number to 574. Four of the original cases also had updated outcome reference diagnosis from the 3-year data. The updated diagnostic accuracy is based on new 
neuroimaging studies up to age 3 years and presented as a percentage along with the percentages correct from the original MERIDIAN study for reference. 
iuMRI=in-utero MRI. *McNemar’s test between ultrasound and iuMRI correct diagnoses.
Table 3: Updated diagnostic accuracy of ultrasonography and iuMRI by gestational age of fetus
Figure 2: Developmental outcome for cognition, language, and motor skills of iuMRI and ultrasonography by 
prognosis13 
The box represents the first (bottom) and third (top) quartiles, the line through the centre of the box represents 
the median. The lower whisker extends from the smallest observation greater than or equal to the first quartile 
minus 1·5 × IQR and the upper whisker extends to the largest observation less than or equal to the third quartile 
plus 1·5 × IQR. iuMRI=in-utero MRI. 
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a good or poor prognosis.
When the inal prognosis based on iuMRI was normal 
or favourable, this was often correct. The second reason 
relates to the efect of non-uptake of the 3-year 
developmental assessment. Although the reasons for 
non-participation are speculative, fetal and infant 
mortality (excluding termination of pregnancy) were 
marginally lower after a favourable or normal prognosis 
from iuMRI than ultrasonography, and higher following 
a poor iuMRI prognosis than a poor ultrasonography 
prognosis. Similar patterns were seen for frequency of 
pregnancy terminations. Therefore, although iuMRI was 
superior to ultrasonography for identifying children with 
normal development, the two modalities were similar in 
their ability to predict abnormal development.
A further consideration relates to how we deined 
developmental outcomes. The mean population score of 
the BSID3 is 100 (SD 15), so around 95% of the normal 
population lie between 70 to 130.10 These scores are in 
keeping with the deinition of early developmental 
impairment—in which developmental abilities have to 
fall two standard deviations below the population mean 
in two or more domains17,18—and the International 
Statistical Classiication of Diseases, 10th revision, 
classiication of mild learning disabilities when an 
intelligence quotient (IQ) is 50–69, moderate when 
35–49, severe when 20–34, and profound when below 
20·19 By contrast, preterm follow-up studies, such as the 
EPICure Study,20 deine BSID3 scores between 70 and 
85 as mild impairment, 55 and 70 as moderate, and 
below 55 as severe, or cognitive or language scores below 
85 as moderate to severe impairment.21 
Using these deinitions for fetal follow-up studies 
comes with challenges; for example, a single point could 
be the diference between a normal and moderate to 
severe impairment and might result from the child’s 
tiredness, boredom, or refusal. The deinitions take little 
account of the child’s genetic or social potential: a child 
with a cognitive composite score of 84 whose parents’ 
IQs are also in the 80s might be appropriate, whereas a 
child with a score in the normal range at 88 whose 
parents’ IQs are 130–140 might not. 
Developmental assessments at 2–3 years are imperfect 
predictors of later outcome,22–25 because children scoring 
normally in the early years might exhibit signiicant 
di culties later, and children with low scores might 
catch up to their peers. Therefore, care is needed, 
especially because terminology like severe or abnormal 
strongly inluence patient choice,26–28 and we do not wish 
to inlate the risk of developmental problems and 
inadvertently coerce women towards terminating fetuses 
who would be normal.
Another issue was the proportion of participants 
assessed only with the ASQ3, which can yield false-
positive results.29–31 A number of children who were 
identiied by the ASQ3 as borderline or abnormal, scored 
normally on the BSID3 (appendix p 5). For these reasons, 
we chose the term at risk rather than mildly abnormal or 
borderline because these children might have normal 
outcome in the long term. We were similarly careful not 
to classify all participants with cerebral palsy as abnormal. 
This might seem a controversial choice, but women 
report that health-care professionals focus too much on 
medical diagnoses and terminology during antenatal 
counselling, when what they really want to know is the 
best and worst case scenario and the likely functional 
outcome of their baby.32–34 
The views are consistent with a WHO report on 
disability,35 which notes that generalisations about 
disability are misleading because many people with a 
disability do not consider themselves unhealthy or to 
have a bad quality of life. WHO suggests clinicians’ focus 
should be directed less towards medical diagnosis and 
more towards how it impairs an individual, afecting 
activity, participation, and independence. With this in 
mind, categorising a child with mild cerebral palsy—
whose GMFCS scores are low and whose motor scores 
on BSID3 and ASQ3 are normal—as severely abnormal 
is inappropriate, particularly given they are likely to have 
normal quality of life.36 Therefore, we categorised 
functionally able children with cerebral palsy as at risk.
Although the number of participants in project two 
was lower than anticipated, our indings indicate that, 
despite the increase in diagnostic accuracy and coni-
Developmental assessment (surviving 
infants)
In-utero death, 
stillbirth or infant 
death (n=65)
Normal or at risk 
(n=111)
Abnormal  
(n=45)
Ultrasonography
Normal or favourable (≤10%) 56 13 11
Specificity 50% (41–60) ·· ··
NPV (surviving infants only) 81% (70–89) ·· ··
Intermediate (11–50%) 28 11 15
Poor (>50%) 5 9 27
Sensitivity ·· 20% (11–34) 42% (30–54)
PPV (surviving infants only) ·· 64% (39–84) NA
Unknown 22 12 12
iuMRI
Normal or favourable (≤10%) 76 19 10
Specificity 68% (59–76) ·· ··
NPV (surviving infants only) 80% (71–87) ·· ··
Intermediate (11–50%) 20 12 16
Poor (>50%) 5 11 31
Sensitivity ·· 24% (14–39) 48% (36–60)
PPV (surviving infants only) ·· 69% (44–86) NA
Unknown 10 3 8
Data are n or % (95% CI). Prognosis following in-utero scan (chance of abnormal development as assigned by 
clinician). NA=not applicable. iuMR=in-utero MRI. NPV=negative predictive value. PPV=positive predictive value.
Table 4: Outcomes of infants based on in-utero ultrasonography and iuMRI prognosis where imaging 
was done within 2 weeks of each other, along with specificities, sensitivities, PPV and NPV
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dence provided by iuMRI, it remains di cult to predict 
clinical outcomes on an individual basis. This result is 
unsurprising because prognostication data from 
antenatal studies are based on population studies rather 
than individualised risks for speciic fetuses, and the 
efect of a given brain abnormality can vary markedly 
between individual infants. 
A more appropriate way to analyse project two might 
be on a grouped basis: the data shown in table 5 indicate 
that if a poor prognosis is made on the basis of 
ultra sonography data alone, 69% of those fetuses have 
an abnormal outcome; the results using iuMRI 
information are similar (72%). These igures are 
consistent with the more than 50% chance used in our 
deinition of poor prognosis. An intermediate prognosis 
based on ultra sonography data is associated with the 
chance that 29% have an abnormal outcome, whereas an 
intermediate prognosis on iuMRI is associated with a 
higher chance of an abnormal outcome (42%). Both fall 
into the 11–50% range used to deine intermediate 
prognosis. 
Fetuses given an unknown prognostic category had 
clinical outcomes similar to the intermediate category, 
with abnormal outcomes in 38% from ultrasonography 
information and 31% based on iuMRI information. The 
results from the normal and favourable categories 
showed the widest discrepancy when compared with the 
predicted abnormal risk rates. 
The predicted risk of an abnormal outcome when those 
two groups are merged is 10% or less but the observed 
abnormal outcome rates were 21% for ultrasonography 
and 19% for iuMRI-derived data. This inding was 
unexpected and concerning because they are double the 
expected percentage of abnormal outcomes in cases 
which, presumably, had normal or minor indings on 
ultrasonography and iuMRI. Further analysis is planned 
to study the nature of the abnormalities associated with 
abnormal outcomes.
Other possible explanations exist for the modest 
correlation between the prognosis and developmental 
outcome. One is the lack of high-quality developmental 
outcome data after fetal diagnosis of neurological 
abnormalities. A second is that there might be other 
factors inluencing an obstetrician’s prognostication, 
such as maternal health, family history, fetal growth, or 
amniotic luid volume, or where a combination of fetal 
abnormalities are found. As such, counselling must be 
tailored to an individual’s situation, and the MERIDIAN 
study cannot analyse the subtleties of a clinician’s 
thoughts or hunch. A third is the experience of the fetal 
medicine expert in inter preting the signiicance of 
paediatric neuro imaging: a survey of fetal medicine 
consultants done during the MERIDIAN study showed a 
wide range of prognostic grades would be given for the 
same antenatal imaging indings.37 
Further research is needed to determine whether a 
paediatrician with experience in following up children 
with neurodevelopmental abnormalities might interpret 
antenatal imaging indings diferently and provide better 
prognostication.
In many ways, the limitations of ultrasonography and 
iuMRI to prognosticate should not be surprising: most 
children with early developmental impairment have 
normal neuroimaging,38,39 and it is common for children 
with abnormalities on neuroimaging to do better 
developmentally than expected. 
In the future, gene exome work might help with 
prognosis, but it is unlikely to give clinicians all the 
information they want. For example, the PAGE study40 of 
610 fetuses with structural abnormalities found a 
diagnostic genetic result in only 8·5% and a result of 
uncertain clinical signiicance in 3·9%. The challenges 
of delivering exome studies in a timely manner in 
antenatal care also need to be overcome, along with 
explaining to families the problem of phenotypical 
variation between individuals with the same mutation, 
even within a single family.41,42
Project three looked at children who had IMVM. 
Most children with this antenatal diagnosis do not show 
adverse developmental outcomes, so fetal maternal 
clinicians usually give a favourable prognostic category. 
Speciically, just over half of the fetal maternal clinicians 
referring into the MERIDIAN study give a 90% chance of 
a normal outcome and the others 95% normal outcome 
(ie, all have >90% change of normal outcome).37
Large studies and meta-analyses suggest abnormal 
developmental outcome rates in IMVM are 5·6–12%,43–45 
although studies difer in how IMVM is deined, with 
Prognosis based on ultrasonography Prognosis based on iuMRI*
Proportion with abnormal 
development postnatally
Proportion with abnormal or 
at-risk development postnatally
Proportion with abnormal 
development postnatally
Proportion with abnormal or 
at-risk development postnatally
Normal or favourable (≤10%) 18/85 (21%) 30/85 (35%) 21/109 (19%) 38/109 (35%)
Intermediate (11–50%) 14/49 (29%) 20/49 (41%) 15/36 (42%) 20/36 (55%)
Poor (>50%) 11/16 (69%) 11/16 (69%) 13/18 (72%) 15/18 (83%)
Unknown (not known) 15/40 (38%) 23/40 (58%) 5/16 (31%) 7/16 (44%)
iuMRI=in-utero MRI. *The decreased number of iuMRI relates to 11 who had no prognostication information offered by the obstetrician.
Table 5: Prognosis estimated by fetal medicine unit based on ultrasonography and iuMRI for all participants, irrespective of the time between 
ultrasonography and iuMRI
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some studies using 10–11 mm and others 10–15 mm. 
Furthermore, some studies only consider a fetus as 
having IMVM when the karyotype and congenital 
infection screen is negative, others rely purely on the 
absence of other structural abnormalities on imaging.
We took a pragmatic approach because women might 
refuse karyotyping if they considered the risk of 
miscarriage related to amniocentesis or chorionic villus 
sampling too high. We also reviewed the medical notes 
and diagnoses of children for this study, and would 
have recognised children with genetic conditions 
diagnosable by karyo type antenatally and would have 
excluded these, but no such cases were identiied. 
The results of our study show the risk of an abnormal 
outcome was much higher at 22%, and a further 14% 
were considered at risk. The high prevalence of mild 
ventriculomegaly cases in MERIDIAN might partially 
explain the high proportion of abnormal outcomes in 
fetuses given normal or favourable prognostic categories, 
with selection bias also potentially playing a role because 
parents with concerns about their child’s development 
might have been more likely to enrol. 
The false-positive rate of the ASQ3 might also play a role. 
We found a higher rate of abnormal outcome when mild 
ventriculomegaly was associated with other abnormalities, 
such as somatic malformations or chromosomal abnorm-
alities, and the risk of adverse developmental outcomes 
was lower when ventriculomegaly resolved in utero, which 
conirms previous data.44
The key limitation in the MERIDIAN 3-year follow-up 
was the low level of participation, with just under a third 
of eligible parents giving consent to developmental 
assessment. The efect of this is di cult to predict, but 
is likely to be non-random: previous work suggests that 
some parents choose not to participate in research 
because the burden outweighs the beneit,46,47 which in 
this study might arise either for children with no 
obvious problems or for those with clearly abnormal 
development who usually require multiple other 
hospital appoint ments. This reduces the statistical 
power and precision, but more importantly might have 
led to either an over-estimation or an under-estimation 
of the incidence of abnormal development. 
We cannot be more speciic without knowing the 
reasons parents chose not to participate. By contrast, any 
selection efect is less likely to afect the direct comparison 
between iuMRI and ultrasonography, particularly the 
sensitivity and speciicity for predicting abnormal 
development.48 We also were not able to administer 
BSID3 to all participants, relying on the ASQ3 in a 
proportion. Direct comparison between the two tests 
shows good agreement, but false positives on the ASQ3 
might have inlated the abnormal and at-risk groups. 
Finally, we limited the analysis of development to 
surviving infants. An alternative analysis would be to 
incorporate both surviving and non-surviving cases 
using survey-based weighting to account for their 
diferential probability for inclusion. The di culties in 
interpreting these measures, in particular for cases 
managed by termination of pregnancy, led us to focus 
on outcomes conditional on the infant surviving to age 
3 years. These exclusions will have underestimated the 
true diagnostic and prognostic ability of iuMRI, given 
its ability to identify severe brain conditions.
Despite a low level of participation, we conirmed that 
the original postnatal diagnosis remained applicable for 
the majority of infants at their 3-year follow-up. We did 
not collect information on why additional investigations 
were (or were not) undertaken, and it is likely that a 
proportion of infants had more latent complications that 
had either not been diagnosed or not become apparent. 
Despite our concerns about the veracity of ORD from 
neuroimaging studies before 6 months of life, the updated 
estimates of diagnostic accuracy of ultra sonography and 
iuMRI for detecting fetal brain abnormalities are 
exceptionally close to the original calculations and conirm 
the diagnostic advantage of doing iuMRI. 
The indings from the clinical follow-up show iuMRI 
improves the conidence of the fetal medicine unit team 
to say a fetus will have a normal outcome, but 
prognostication of outcome remains similar between 
imaging modalities. Further work is needed to determine 
whether this is a problem inherent with iuMRI or 
whether other professionals, such as paediatricians, can 
help to improve prognostication. 
Finally, our results indicate a much higher rate of 
abnormal outcomes than would be expected in fetuses 
with minor brain abnormalities who were estimated to 
have normal or favourable prognosis antenatally. This is 
particularly the case in fetuses with mild ventricu-
lomegaly that does not resolve in pregnancy, and larger 
cohort studies are needed to determine what the exact 
risk is and which fetuses are at the greatest risk.
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